Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885016 | 0.82 | PDE10A (0.47) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL12677961 | 0.81 | CRHBP (0.49) | KMT2ACRHBPCRHR2NPSR1ALDH1A1 | |
| SCHEMBL1713997 | 0.79 | KMT2A (0.40) | KMT2ACRHBPCRHR2HRH4ALDH1A1 | |
| SCHEMBL2401439 | 0.79 | HTR3A (0.58) | NPSR1HRH4ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL15582906 | 0.79 | KMT2A (0.42) | KMT2ACRHBPCRHR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL12186838 | 0.78 | KMT2A (0.41) | KMT2ACRHBPCRHR2NPSR1ALDH1A1 | |
| SCHEMBL19581824 | 0.78 | KMT2A (0.41) | KMT2ACRHBPCRHR2NPSR1ALDH1A1 | |
| SCHEMBL3089415 | 0.78 | KMT2A (0.64) | KMT2ACRHBPCRHR2ALDH1A1HTT | |
| SCHEMBL5524143 | 0.78 | ALDH1A1 (0.44) | KMT2ACRHBPCRHR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL245740 | 0.78 | KMT2A (0.49) | KMT2ACRHBPCRHR2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2240452-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES AS PI3 KINASE MODULATORS, THEIR COMPOSITIONS AND USES | INTELLIKINE LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010077686-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | KMT2A 2988/4885CRHBP 4683/4885CRHR2 4643/4885 |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KMT2A 2601/4885CRHBP 1097/4885CRHR2 2308/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | KMT2A 2988/4885CRHBP 4683/4885CRHR2 4643/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | KMT2A 2089/4885CRHBP 4584/4885CRHR2 4689/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | KMT2A 985/4885CRHBP 4075/4885CRHR2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.